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ABSTRACT 
Key, Marc E., M.S., August 1976 Ivlicrobiology 
The Immune Response to Malignant IVielanoma in Mice Treated 
With Phytohemagglutinin (82 pp.) 
Director: Carl L. Larson 
The effects of phytohemagglutinin (PHA) treatment of 
mice on the development of specific tumor immunity and the 
subsequent effect of this on tumor growth was investigated. 
PHA treatment was shown to reduce the survival time of mice 
bearing grafted Bl6 melanoma cells and also increased the 
development of lung metastases after intravenous tumor 
challenge. 
To confirm the immunosuppressive nature of PHA, the 
cellular and humoral immune responses of mice to other 
antigans was studied, PHA reduced the antibody response of 
mice to sheep red blood cells and reduced the delayed 
hypersensitivity response to Mycobacterium bovis (BCG). 
The specific effects of PHA on the immune system were 
studied by various in vitro cytotoxicity assays. Macrophage 
cytotoxicity tests revealed no differences between 
macrophages from tumor-bearing mice treated with PHA and the 
macrophages from untreated tumor-bearing mice. Similarly, 
assays for the presence of serum blocking factors revealed 
no significant differences between tumor-bearing mice 
whether or not they were treated with PHA. 
Lymphocyte cytotoxicity tests showed that lymphocytes 
from tumor-bearing mice treated with PHA were delayed in the 
development of specific tumor immunity compared to lymphocytes 
from untreated tumor-bearing mice. Lymphocytes from PHA-
treated mice were capable also of stimulating tumor cell 
proliferation jji vitro. 
From these studies a model was proposed to account for 
the apparent increased suseptibility of mice to Bl6 tumor 
cells after PHA treatment. 
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CHAPTER 1 
INTRODUCTION 
Phytoheniciggulutinin (PHA), an extract from the red 
kidney bean, Phaeseolus vulgaris, has been used since the 
early 1900s for agglutinating red blood cells. Landsteiner 
(65), who first discovered these hemagglutinating properties, 
did much of the early work on this aspect of PHA at the turn 
of the century. It was not, however, until 1959 that the 
raitogenicity and blastogenicity of PHA for human lymphocytes 
were discovered (74). This substance could induce the 
transformation of small lymphocytes from human peripheral 
blood into large lymphoblastoid cells capable of undergoing 
mitotic division. Plant mitogens such as PHA could activate 
lymphocytes to undergo blast transformation without prior 
antigenic stimulation (?6, 77)• Lymphocytes from the 
umbilical cord blood of newborns are fully capable of 
responding to PHA even though they are presumably free from 
any prior antigenic exposure. In contrast, most antigens 
stimulate lymphocytes only from previously sensitised donors, 
and antigens have no ef1ect on cord blood lymphocytes (76). 
This discovery of PHA-induced lymphocyte proliferation had 
a great impact on the field of immunology since up until this 
time it was believed that lymphocytes were essentially end 
cells, incapable of undi^rgoin.": further cell division. 
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PHYSICAL, AKD BIOLOGICAL PROPERTIES GP PHA 
Physical and Chemical Characteristics 
Rigas and Osgood (86) in 1955 successfully isolated the 
hemagglutinin of kidney hearts. The isolated components 
included a simple protein (PHA-P) and a mucoprbtein (PHA-M). 
The PHA-P behaved as a homogeneous substance by electrophoresis 
over a pH range from 2.0 - 8.0 and had an isoelectric point 
of 6.5. The mucoprotein also migrated as a homogeneous 
substance on electrophoretic analysis between pH 5,8 - 8.6 
but dissociated into a protein hemagglutinin and an inactive 
polysaccharide below pH 5*8. Both fractions (PHA-P and PHA-M) 
could individually agglutinate red blood cells obtained from 
various mammalian species. In 1964 Rigas and Johnson (85) 
isolated a protein pytohemagglutinin from Phaeseolus vulgaris 
which was homogeneous by ultracentrifugation, electrophoresis, 
and column chromatography. The molecular weight of this 
protein was 128,000, and this protein v/as found to possess 
both hemagglutinating and mitogenic activities. 
Chromatographic separation of a commercially prepared 
PHA-P by Weber et al. (105) yielded three separate peaks. 
The fraction obtained in the first peak lacked both 
hemagglutinating and mitogenic properties.. The material in 
the second peak possessed strong mitogenic properties but 
lacked hemagglutinating activity, while that in the third 
peak contained both a strong hemagglutinin and a weak 
mitogen. Thus, at least tv/o distinct mitogenic factors 
separable by their different chromatographic behaviors were 
identified. 
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has also been shown to cause leukocyte aggulatina-
tion. Hastings et. al (44) observed that when lymphocytes 
were stimulated with PHA, cell division occurred primarily 
in white blood cell clumps which suggested that theleuko-
açglutinin was also responsible for the mitogenic activity. 
Kolodney and Hirschhorn (63) found that adsoprtion of PHA 
with red blood cells could effectively remove the hemagglutinin 
without affecting the leukoagglutinating or mitogenic 
activities of the PHA. However, adsorption with white blood 
cells removed all three properties. These studies indicated 
an apparent relationship between the leukoagglutinating and 
mitogenic properties of PHA, 
Prom these studies it was apparent that PHA was not a 
single component but was composed of multiple fractions. 
PHA contained a hemagglutinin which could bind not only 
erthrocytes but also leukocytes and could be removed by 
erythrocyte adsorption without any apparent loss in mitogenic 
activity. This material might be identical to the third 
fraction of Weber et al. (IO5) obtained by chromatographic 
separation which contained a strong erythroagglutinin and a 
weak mitogen. PHA also contained a second fraction with 
both leukoagglutinating and mitogenic properties. Adsorption 
with leukocytes removed both activities while adsorption 
with erythrocytes had no effect. This material might be 
identical to the second fraction of Weber and coworkers (IO5) 
which was found to contain mitogenic but not hemagglutinating 
properties. 
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Lymphocyte Surface Receptors for PHA 
The possibility that sugar receptor sites might play a 
role in the interaction between PHA and lymphocytes was first 
investigated by Borberg et. al. (l4). They showed that 
henrmagglutination and leukoagglutination by PHA could be 
inhibited by the addition of N-aoetyl-D-galactosamine to 
cell cultures. In a later study Borberg et al. (15) also 
showed t!iat in PHA-stimula ted lymphocyte cultures, 
N-acetyl-D-galactosamine could inhibit DM and RNA synthesis, 
thus preventing mitosis. These studies were later confirmed 
by Fisher and Mueller (3^) who found that N-acetyl-D-
galactosamine competed with lymphocytes for tlie binding of 
and inhibited PHA-induced lymphocyte proliferation. 
One explanation for the suppressive effects of N-acetyl-D-
galactosamine on PHA-induced lymphocyte responses, was that 
this sugar interfered with the normal binding of PHA to cell 
surfaces. Perhaps N-acetyl-D-galactosamine v/as an integral 
portion of the cell wall and the receptor site to which PHA 
attached. Free N-acetyl-D-galactosamine would then compete 
with these cellular sites for PHA binding, thus reducing the 
availability of PHA to the cell. 
Allen (3) has estimated tiiat a single lymphocyte 
contained in excess of 6 x 10^ receptor sites for PHA. 
Iviitogenic response was greate t when only 3 - lO'/i of tiie total 
binding sites were occupied by PHA and v/as reduced when a 
larger number of recpetors were bound. 
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Apparently tlie interaction of PHA with the cell menbrane 
was a necessary step in the stimulation of lymphocytes. 
Thymus-dependent Lymphocyte Specificity of PlIA 
Despite the fact that PHA was readily bound to both B-
and T-lyniphocytes (4l), many investifations have shown that 
PHA could activate only ï-lymphocytes (6, 37, 75. 76, 79, 96). 
Some of the early evidence for the T-cell specificity of PHA 
came from the study of patients with congenital immune 
deficiency diseases. Patients with DiGeorge syndrome 
(thymic agenesis) were unable to develop cell-mediated 
immune responses, although they were capable of synthesizing 
some immunoglubulins (75)• Lymphocytes from these patients 
also failed to respond to PHA which suggested that lymphocytes 
mediating cellular i; .mune responses might also be the same 
lymphocytes which were responsive to PHA (75). An analagous 
situation was found in congenitally athyraic "nude" mice 
whose lymphocytes also failed to respond to PHA jjn vitro (76). 
I.iethods for separation of id- and T-cells also have 
supported the concept of the T-cell specificity of PHA. 
Purified populations of T-lymphocytes responded well to PHA 
while purified B-cell populations did not (6, 37» 96). 
However, activation of B-cells has been shown to occur in 
mixed populations of B- and T-cells. Piguet and Vassoli (79), 
using thyniectouiized, irradiated mice, reconstituted with 
genetically distinguishible thymus cells, were able to 
differentiate between donor thymus cells and recipient 
B-lymphocytes. They concluded by tiis technique tnat, while 
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the early migtogenic response to PllA was due mainly to T-cells, 
after 3 days a significant number of B-cells also were 
responding. Goldschneider and Cogen (39) found that yfo of 
PHA-transformed lymphocytes gave positive staining reactions 
with flourescent-labeled anti Ig which indicated a limited 
B-cell responsiveness. Apparently in mixed lymphocyte 
populations, both B- and T-cells could respond to PHA by 
undergoing cell division. In purified populations, however, 
only T-cells responded while B-cells did not. Anderson 
et al. (5) and Piguet and Vassoli (79) have concluded that 
T-cell mitogens could stimulate T-lymphocytes to release 
substances which acted upon B-cells to induce their 
proliferation. 
Although PhA apparently binds to all lymphocytes, only 
a certain percent will Espond by undergoing cell division. 
Rubio and Zajicek ( 9 2 )  reported that 70 - 90^ of human lymph 
node lymphocytes were transformed after 3 days incubation 
with PHA. Similar results were reported by Bach and 
Hirscbhorn (8) for PHA-stimulated cultures of peripheral 
blood lymphocytes. However, Jones (59) felt that these 
estimates were falesly elevated due to early cell death and 
loss of lymphocytes. He estimated that PHA stimulated only 
11 - 26$ of splenic lymphocyte populations. Stoiio and 
Paul (101) felt that only a subset of T-lymphocytes responded 
to PHA, They described this subset as consisting of 
recirculating cells, sensitive to anti-lymphocyte serum, and 
relatively resistant to radiation. In contrast, another 
T-cell subset, responsive to tiie T-cell mitogen concanavalin-A, 
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was relatively sessile, radiosensitive, and more resistant 
to anti-lumphocyte serum. Some evidence has been presented 
recently that this PHA-responsive subset might include a 
suppressor T-cell population which could suppress normal 
antibody production by B-cells (84). 
BLAST TRAl-^SFORMTION OF PHA-STIMULATED SY1..-PHOCYTES 
WorpholoKical Changes 
The morphological changes observed by light microscopy 
in small lymphocytes stimulated with PHA have been described 
extensively (22, 71, 87). The small lymphocyte, prior to 
stimulation, contained a large nucleus with condensed 
chromatin. The nucleus was surrounded by only a narrow ring 
of slightly basophilic cytoplasm. V/ithin 24 hr following 
the addition of PHA to lymphocyte cultures, nuclear and 
cytoplasmic changes were observed. The cytoplasim volume 
increased and became more basophilic, while the nucleus was 
found frequently to contain a nucleolus. Between 24 and 48 
hr of culture, typical blast cells appeared which contained 
abundant deeply basophilic cytoplasm. A lighter perinuclear 
zone representing Golgi apparatus was present. The cytoplasm 
of these blast cells was pyroninophilic indicated active 
RNA synthesis. Between 4o and 72 hr of culture numerous 
mitotic figures were ousorved. 
Tonaka et al. (IO3) and Inman and Cooper (5^) studied 
the morphology of PHA-stimulated human lymphocytes by 
electron microscopy. After 72 hr of culture in tiie presence 
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of PHA, nucleoli were always present, the cytoplasm contained 
numerous ribosomes and mitochondria, and Golgi apparatus v/as 
well developed. These changes were interpreted as indicating 
increased protein synthesis and mitotic activity in 
stimulated cells. 
Effects on i\uclelc acid and Protein Synthesis 
Several metabolic changes occurred in lymphocytes 
undergoing blastogenesis in the presence of PHA. Through 
the use of radiolabeled precursors, the synthesis of DNA, 
RNA, and protein has been studied in PHA-stiraulated lympocyte 
cultures (23, 68, 73» 94). 
The earliest changes observed by Cooper and Robin (23) 
in cultures of PHA-stimulated lymphocytes, were a decrease in 
total RNA detectable within the first 30 min. Accelerated 
RNA synthesis was apparent after 1 hr. as measured by the 
incorporation of tritiated uridine, and continued for 24 hr. 
Analysis of the newly formed RM in sucrose gradients 
revealed that the synthesis of all classes of RNA was 
stimuIsted by PHA (73). 
DNA synthesis was observed beginning 24 hr after the 
exposure of lymphocyte cultures to PHA as measured by the 
incorporation of tritiated thymidine into newly formed 
DNA (68). Tlie percentage of cells synthesizing DNA increased 
lo>:ari thill Lcally from approximately 22 hr of incubation to 
52 hr of incubation and was followed by significant mitotic 
activity. 
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Protein synthesis in lymphocyte cultures incubated with 
PHA has been studied by Sell and coworkers (94). They 
observed that stimulation of rabbit lymphocytes with PHA 
was followed by an increase in protein synthesis. Both 
stimulated and unstimulated lymphocytes incorporated 
radioactive lysine into protein during the first 24 hr, but 
only PHA-stimulated lymphocytes continued to synthesize 
protein during the second 24 hr period. Turner and Forbes 
(l04) cultured hujnan peripheral lymphocytes in the presence 
of PHA and used the incorporation of ^^C-amino acids into 
protein as an indicator of protein systhesis. Analysis of 
the culture supernatant fluids by startch-gel electrophoresis 
and DEAE-cellulose column chromatography showed that a broad 
range of proteins containing radioactive material could be 
indentified, although the label was strongest in the alpha 
2 M-globulins and haptoglobins. Back and Hirschhorn (7) 
found that 5 x 10^ lymphocytes could synthesize approximately 
10 ug of protein during a 24 hr incubation period with PHA. 
Effects on Cyclic ALP Levels 
Another early event in PHA-induced lymphocyte activation, 
detectable within the first 20 min, was an increase in 
intracellular levels of 3'. 5'-oyclic adenosine monophosphate 
(cAmP) (98). Chloropromazine, an inhiuitor of cAwP synthesis, 
blocked the mitogenic stimulation of lymphocytes demonstrating 
the importance of cAr.iP (24). The exact mechanism of action 
of cAMP on activation, however, has not been clearly defined. 
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THE EFFECT OF PHA ON THE IMviUNE RESPONSE 
Antibody Production 
Since the discovery that PHA could cause nonspecific 
proliferation of lymphocytes in vitro, its possible role in 
enhancing the immune response has come under study by many 
investigators, iv.ost of these studies have centered around 
the effects of PHA on the humoral immune response. Despite 
numerous reports appearing over the past fev/ ye&rs, no 
definitive conclusions on the effects of PHA on antibody 
responses have been reached. Apparently numerous complex 
factors determine whether PHA will enhance or inhibit 
antibody production to a given antigen. 
The administration fo PHA intraperitoneally to rats 
24 hr prior to challenge with chick red blood cells caused 
a significant reduction in antibody production (30). In 
contrast, if PHA was given 6 hr after antigenic challenge, 
antibody production v/as enhanced (30). PHA has also been 
shown to have a similar effect in mice on their antibody 
response to sheep red blood cells (18, 29). Antibody 
production was decreased in mice receiving PHA intraper­
itoneally prior to sheep red blood cells but was enhanced 
when given after the sheep blood cells. Simultaneous 
administration of PHA with sheep red blood cells caused no 
significant changes in antibody titer. Jennings and Oates 
(57) reported a reduced primary and secondary immune 
response to sheep red blood cells in both rats and mice when 
PJIA v/as j iven intraper j toi ieal ] y 1 to 2 days before the 
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antigen. Gengozian and llubner (38) also observed a decreased 
antibody response in mice to Salmonella typhosa when PHA was 
given 1 day before the antigen. In contrast, the prior 
administration of PHA intravenously enhanced antibody 
production in mice to rat red blood cells (36) and in rabbits 
to sheep red blood cells (97). 
Using tiie Jerne plaque assay technique (3^)> Spreafice 
and Lerner (99) demonstrated that the intraperitoneal 
injection of PHA simultaneously with, or prior to, the 
intraperitoneal injection of sheep red blood cells caused a 
significant depression of both the primary and secondary 
immune response. On the other hand, the injection of PHA 
after the antigen had no effect on the plaque forming cell 
response. However, the direct addition of PHA to a Jerne 
plaque assay after 48 hr of culturing sensitised mouse 
spleen cells in the presence of sheep red blood cells, 
increased the plaque forming cell response (84). 
From these studies it is apparent tiiat both the route 
of administration of PHA and timing of injection in relation 
to the antigen were important factors in determining whether 
antibody production was enhanced or decreased. Other factors 
which might influence the antibody response to PHA and must 
be considered were the type of animal under investigation, 
the amount of PHA injected, and the amount of antigen given. 
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The Effect of PHA on Gell-l.iediated Immune Responses 
Lyraphokine Production-
Lymphocyte cultures treated in vitro with PHA have been 
shown to produce numerous lymphokines similar to those 
produced by sensitzed T-lymphocytes in response to specific 
antigen. Jeffes and Granger (55) have shown that PHA-
stimulated lymphocytes released lymphotoxin, proliferation 
inhibition factor, and cloning inhibition factor. The studies 
of many investigators have documented the destructive effects 
of PlIA-stimulated lymphocytes on target cells (13» 40, 51-53) • 
These lymphocytes were either directly cytotoxic or released 
cytotoxic substances which could kill a large variety of 
both syngeneic or allogeneic target tumor cells. Other PHA-
induces lymphokines which have been reported include 
macrophage migration inhibition factor (64), skin reactive 
factor (78), and interferon (35). 
Delayed Hypersensitivity-
The relase of lympnokines by PHA-stimulated lymphocytes 
is in many ways similar to the lymphocyte response triggered 
by specific antigen. Because of this apparent similarity 
the effect of PHA on cell-mediated immune responses has been 
investigated closely, Schrek and Stefani (93) found that the 
intradermal injection of PHA in human volunteers produced an 
inflai matory response with maximal induration at 24 hr similar 
to a delayed hypersensitivity reaction. Otner investigators 
also have observed a similar response to the intradermal 
i n j i; c t i o 11 o f PHA ( 1, 6 7 ). 
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Apparently the localized injection of PilA could elicit 
an inflammatory response at the site of injection. On the 
other hand, the injection of PHA intraperitoneally or 
intravenously might be expected to trigger a systemic 
stimulation of lymphocytes and release of lymphokines, thus 
rendering; tnem less responsive to a localized antigenic 
challenge and reducing their ability to produce a local 
inflammatory response. 
Tne systemic treatment of mice, rats, and rabbits with 
PHA has, in fact, been shown to depress cell-mediated 
immune responses. Stevens and Willoughby (lOO) have invest­
igated the effect of PHA on the expression of delayed 
hypersensitivity in rats to pertussis vaccine. PHA was 
administered intravenously prior to the injection of 
pertussis vaccine and then daily for 12 days dollovving the 
vaccine injection. A decreased inflammatory reaction, 
following antigenic challenge on day 12, was observed. If 
PHi'i was given only 24 hr prior to the challenging dose, no 
reduction in the infla/iinatory response resulted. 
Graft Survival-
jvlarkley et al. (70) administered PHA intraperitoneally 
into rabbits beginning 2 days before the placeiuent of a skin 
allograft in the rabbit's ear and continuing daily until the 
graft was rejected. PHA increased the survival time of the 
allograft from an average of 6.9 days to 15.2 days. More 
receiving daily injections of PHA for 3 consecutive days 
followed by allogeneic skin grafting on day 4, retained the 
14 
skin ,«;r£ft longer than untreated controls (102). On the 
other hand, a single injection of PHA either 24 hr before or 
after the time of skin grafting did not increase graft 
survival time in mice (60). 
Effect of PHa on Tumor Growth-
Robinson and Wekori (90) investigated the eii'ect of PHA 
treatment on ascites tumor cell survival in mice. PHA was 
administered to mice intraperitoneally at various time 
intervals prior to, or subsequent to, the intraperitoneal 
injection of ascites tumors. Seven days after the injection 
of tumor cells, the peritoneal cavity was washed, and the 
packed cell volume was determined. Robinson and Mekori 
found a reduction in packed tumor cell volume compared to 
control mice when PîiA was administered 72 hr prior to tumor 
cell implantation. However, treatment with PHA 120 hr before 
tumor implantation resulted in an increased tumor volume on 
day 7. Robinson and Iiekori suggested that PHA-"modified" 
lymphocytes were able to destroy tumor cells _in vivo. The 
effect of PHA apparently was a transient one and might, in 
fact, act to reduce lymphocyte cytotoxicity in the long run 
as indicated by the increased tumor cell volume when PHA was 
given 120 hr prior to tumor cell injection. However, based 
upon these results, itie tentative use of PHA in cancer 
patients was tried, and some temporary improvement was 
reported (88, 89). Mobley et al. (72) also showed a slight 
increased survival time in PHA-treated mice given Erlich 
ascites tumor cells. i..ice given tumor cells intraperitoneally 
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followed by treatment with PHA on days 1, 3, and 5i had a 
mean survival time of 10.6 days, while control mice had a 
mean survival time of less than 8 days. Although this 
difference was not highly significant (p> 0.05,^ 0.1), 
perhaps PHA could exert some early tumor-inhibiting effects. 
In contrast, neit'.ier Datta et al. (25) nor Hubio and 
Unsgaard (91) could find any protective effects of PHA on 
ascites tumor growth in mice. 
SUMMARY 
The plant lectin, phytohagglutinin, isolated from beans 
of the genus Phaeseolus. has been shown to produce blastogenic 
and mitogenic changes in lymphocyte populations. Lymphocytes 
were also induced to release various lymphokines. Because 
these effects were in many respects similar to the effect of 
specific antigen on sensitized lymphocytes, the effects of 
PHA on immune res onses liave been studied by many investigators. 
In general, it has been found that PHA suppressed both humoral 
and cell-mediated im, iune responses, although in some cases 
PHA was found to enhance antibody formation. 
The effect of PHA on tumor immunity was not clear. The 
in vitro treatment of lymphocytes with PHA could lead to the 
development of cytotoxic lymphocytes capable of destroying 
tumor target cells. Although the early effects of PHA might 
be to modify lympliocytes to kill tumor cells, as was believed 
by Robinson and Mekori (90), it might also act to retard the 
development of specific tumor immunity, thus in the long run 
promo tin;'" tumor ;,x-ov/th. 
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STATEKiENT OF PURPOSE 
Preliminary studies have been performed to determine 
what effect FHA treatment would have on the survival time of 
mice bearing grafted malignant melanoma. The results of 
these studies have shovm that survival time was shortened in 
mice treated with Plià and tumor cells, indicating a possible 
PHA-induced immunosuppression. The purpose of the present 
study was to investigate the effects of PHA on the immune 
system of mice and to determine why pretreatment of mice 
with PHA caused an apparent increased suseptibility to 
malignant melanoma as indicated by their shortened survival 
time. Three different components of the immune system, 
lymphocytes, macrophages, and serum factors, were studied 
to determine whether one or more of these components may be, 
in part, responsible for this apparent increased 
suseptibility. 
CHAPTER 2 
MATERIALS AND METHODS 
MICE 
C57 Black mice, 2 to 5 months old, were obtained from 
the Rocky fountain Laboratory in Hamilton, Montana. Upon 
arrival the mice were held for a 2 week observation period 
and supplied with water containing 300 ug/ml tetracycline. 
They were housed 8-11 per cage and allowed food and water 
ad libitum during the experiments. 
REAGENTS AND TISSUE CULTURE PREPARATIONS 
Minimum Essential Medium CviEM) 
Commercially preparaed powdered MEM (GIBCO, Santa Clara, 
CA.) containing Earle's salts, L-glutamine, and nonessential 
amino acids, was reconstituted with triple distilled water 
and supplemented with Penicillin G (lOO U/ral) and 
Streptomycin sulfate (100 ugV/nl). To increase the buffering 
capacity of the medium, NaHCO^ and N-2-hydroxyethylpiperazine-
N-2-ethansulfonic acid (HEPES, Sigma Co., St. Louis, MO.) 
were added to concentrations of 1.0 mg/ml and 3*57 mg/ml 
respectively, and tlie pH was adjusted to 7.35 witli IN NaOJi. 
The medium was sterilized by filtration t(trough a 0.22 un 
pore size Millipore filter (i.illipore, Bedford, liA.) and 
stored at 4^C. Heat-inactivated fetal calf serum (GIBCO) 
was added to yield a final concentration of 10>i (I.iEM + PCS). 
Thio n:e(i;iuin wr-.s used i n all tents foi' the _in v i.tro f'jrowth 
of tumor celifj. 
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Phosphate Buffered Saline 
Dulbecco's phosphate buffered saline (DPB.S), pK 7 .2 ,  
was prepared according to the method of Dulbecco and Vogt (27) 
and used to harvest and wash spleen cells and peritoneal 
exudate cells. Calcium and magnesium free DPB3 (Pd) was used 
to wash, prior to harvesting, tumor cell monolayers grown 
in vitro. 
Trypsin 
Crystalline porcine trypsin (Sigma) was dissolved in 
HEPES buffered saline (95) to yield a final concentration of 
either 0.05/» (wt/vol) or 0.25^ (wt/vol). The pH was adjusted 
to 7.35 with IN NaOH, and phenol red (10 mg/l) was added as 
a pH indicator. The trypsin preparations were sterilized by 
filtration and frozen until used. The 0.05% trypsin was used 
to remove tumor cells from the bottoms of tissue culture 
flasks, while the 0.25/^ trypsin was used to digest solid 
tumors into single cell suspensions. 
Trypan rlue 
Trypan blue (GIBGO) was used to determine the viability 
of all cell preparations. One part of 0.4^ trypan blue was 
added to 4 parts of the cell suspension and incubated for 5 
min at room temperature. A portion of this mixture was 
added to a Spencer 'Mirigiit Line" hemocytometer (American 
Optical, Buffalo, NY.), and cell counts were performed. 
Cells capable of excluding the trypan blue dye were 
considered viable, and the percentage of visble to stained 
cells was determineci for al] eel] suspensions. 
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F i c o 11 - K y pa q u e 
Lyn.phocyte-rich cell suspensions were prepared from 
mouse spleens by the removal of erythrocytes, granulocytes, 
and macrophages, by centrifugation in a Ficoll-Hypaque 
density gradient. Ficoll (Pharmacia, Uppsale, Sweden) was 
a u t o c l a v e d  a s  a  9 ^  s o l u t i o n  ( v \ f t / v o l )  a n d  a d j u s t e d  t o  p H  7 . 2 .  
Sterile 32.(v/t/vol) sodium riietrizoate (Hypaque) (Nygaard, 
Oslo, Norway) v/as prepared, and 24 parts of Ficoll were 
added to 10 parts of Hypaque. The Ficoll-Hypaque preparation 
was stored at 4°G and protected from light. 
Tris-buffered Ammonium Chloride 
Tris-buffered ammonium chloride, pH 7.65, was prepared 
by mixing 1 part of 0.17M tris buffer (Sigma) with 9 parts 
of 0.(33/'' (v/t/vol) ammonium chloride. This preparation was 
prepared immediately before use and used to lyse erythrocytes 
contaminating the spleen cell preparations. 
Phytoliei agglutinin 
A commercially prepared, dessicated, Phytonemagglutinin-
P (PHA-P), purchased from Difco Laboratories (Detroit, MI.) 
was dissolved to the desired concentration in DPBS 
immediately before use. Mice were injected intraperitoneally 
with 0.2 ml of the PHA-P solution. 
BOG Vaccine 
BCG vaccine, maintained in stock at the Stella Duncan 
Institute, Missoula, Montana, was prepared from Mycobacterium 
bovis (BCG), Paris strain, by growth in Uubos broth (26). 
Cells were w/isited and resuspe ,ded in Dubos brotii to an 
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optical density reading of 200 (K-200) on a Klett-Summerson 
photoelectric colorimeter equipped with a blue filter 
(Klett-Summerson ^42, 400-465 nm). This stock suspension 
was distributed in vials and stored at -70 C. Vials were 
thawed under warm tap water, diluted with an equal volume of 
Dubos broth, and 0,2 ml were injected intraperitoneally into 
mice. This dose contained between 5 x 10^ and 10 x 10? 
colony-forming units of BOG. 
BOG.Protoplasm 
BCG protoplasm was maintained in stock at the Stella 
Duncan Institute and had been prepared by resuspending twice 
washed BCG in distilled water to a concentration of 10 to 15 
gm (wet weight) per 100 ml. Cells were ruptured in a Sorvall-
Ribi cell fractionator at 45,000 psi, and the effluent was 
centrifuged (27.000Xg) for 1 hr to remove cellular debris. 
The supernatant fluid, termed protoplasm, was lypholized and 
stored at -20^0. 
HANDLING OF TbWOR CELLS 
Tumor Cells 
I alignany melanoma (Bl6) tumor cells, obtained from the 
Jackson Laboratory, Bar Harbor, Maine, were used throughout 
these studies. This tumor arose spontaneously in C57B1/6J 
mice as a tumor at the base of the ear (42). 
Preparation of Tumor Cell Pool 
Approximately 1 x 10-5 tumor cells were injected 
suhout;ineou.<.;ly into Uiu nuchal area of /uico. When tae tumor 
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growth had progressed to approximately 10 mm in diameter, the 
tumor was removed to start a uniform tumor cell stock. The 
surface area over the tumor was shaved and disinfected with 
IQfo ethanol, and the skin was dissected on three sides of the 
tumor to form a skin flap. The flap of skin with the 
attached tumor was reflected from the underlying surface, 
and the tumor was removed and minced into small fragments of 
approximately 1 mm in diameter. The tumor fragments were 
washed three times with Pd and them digested for five 
minutes with 0.25/^ trypin. The single cell suspension 
obtained by trypsinization v/as filtered through sterile 
cotton gauze into a conical centrifuge tube containing 
MEiu + PCS. The trypsinization procedure was repeated three 
times, and the single cell sustensions were polled and 
centrifuged for 5 min at 250Xg and 4°C. The supernatant 
fluid was discarded, and the cell pellet was resuspended in 
r.iEM + PCS. Tissue culture flasks (Falcon Products, Oxnard, 
h  ? 
CA.) were seeded at a density of 3 x 10 tumor cells-cm^ 
surface area and grown for 72 hr in a humid atmosphere of 
95/^ air and 5/^ COg at 37^0. After four passages of the 
tumor cells jji vitro. tumor cell monolayers were rinsed 
three times with Pd, and the cells were digested from the 
bottoms of the flasks with 0.0S% trypsin. Tumor cells were 
washed once with kEiVi + PCS and resuspended to a density of 
4 X 10^ viable cells/ml in iviiiivi + PCS containing 10)u (vol/vol) 
dimethyl sulfoxide (J.T. Baker, Phillipsburg, NJ.) added as 
a cryopreservative. One ml amounts of the cell suspension 
were sealed in glass ampules and checked for leads by 
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immersion in a O.O^'/ô methylene blue solution for 30 min at 
4"G. Ar.rpules showing no entry of the dye were frozen in 
95^5 ethanol at -70*0 for 2 hr prior to transfer to liquid 
nitrogen. Tumor cell stocks were stored frozen at -196*0 
in liquid nitrogen until needed. 
Passage of Tumor Galls 
All tumor cells used for _in vitro cytotoxicity tests 
and for in vivo tumor challenge experiments were obtained 
from the same tumor pool stored in liquid nitrogen. To 
prepare the tumor cells an ampule was removed from the liquid 
nitrogen and thawed under warm tap water. The cell suspension 
was removed from the ampule, washed once in iviEM + PCS, and 
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transferred to a 75 cm tissue culture flask. After 72 hr 
of incubation, tumor cells were harvested from the flasks as 
described and resuspended to the diesired concentration in 
IwEW +PC3 for cytotoxicity assays or iviEf.'i without fetal calf 
serum for _in vivo challenge. Tumor cells processed in this 
manner were of consistantly high viability {>95%) as 
determined by trypan blue exclusion. 
EFFEGTS OF PHA ON IMMUNE RESPONSES 
Antibody Production to Sheep Red blood Cells 
ï'o determine the effects of PUA treatment on the ability 
of mice to troduce antibodies to sheep red blood cells, mice 
were injected intraperitorieally with 400 ug of PHA either 
?Ji- hr before or after the injection of sheep red blood cells 
also in li'aper L tonea'l l.,y . Approxlma 11.1 j 2 . If - ..I'ljep red 
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blood cells were Injected per mouse, and 6 days later the 
mice were bled from the brachial artery. The serum was 
separated from the cells, and antisheep red blood cell 
hemagglutinin titers were determined on the complement 
inactivated serum. Titrations were performed in micro-titer 
plates, each well containing 0.25 ml oi' titrated serum, 
0.25 ml of DPiiS, and 0.25 ml of a ifo sheep red blood cell 
suspension in DPBS. Tlie plates were incubated for 2 hr at 
room temperature, and the titer was determined as the 
reciprocal of the highest serum dilution showing agglutination. 
Delayed-llypersensitivity Response to BCG Protoplasm 
l.iice were immunized on day 14 with BCG vaccine and then 
treated at various time intervals with 400 ug of PHA 
intraperitoneally. On day zero 20 ug of BCG protoplasm in 
a 0.03 ml volume were injected into the right hind footpad. 
The left hind footpad was injected with O.O3 ml of DPBS 
only. The footpad thickness was measured 24 hr later with a 
Schnell tester ( U.C. Kroplin, GMBH, Postfach, West Germany), 
and the thickness of the control foot was subtracted from 
the thickness of the BGG challenged foot to determine the 
specific inflammation due to BCG. 
This experiment showed a reduction in the delayed 
hypersensitivity response to BGG in inice pretreated with 
PM. To determine whether tnc effect of PHA was upon 
lymphocytes or macrophages, lymphocyte transfer experiments 
were performed. Spleen cells were prepared by mincing whole 
snlé'.nu through //60 uiet:\i wire t-jcreeas into plastic petri 
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dishes containing 5 ml + PCS per spleen. The dishes were 
incubated for 45 rnin in a humid atmosphere of 95% air and 5^ 
CO2 at 37^*0 to remove most adherent cells. White blood cell 
counts were performed, and the suspenstion was adjusted to 
2.5 X 10^ viable white blood cells per ml. Spleen cells from 
mice immunized with BCG and pretreated with PllA were injected 
intraperitoneally into normal, unimmunized, syngeneic 
recipients. A total of 5 x 10^ cells in a 0.2 ml volume 
were injected per mouse. Recipient mice were challenged 24 
hr later in the footpad with BCG protoplasm. Since recipient 
mice contained normal macrophages but only sensitized donor 
lymphocytes previously exposed to PHA, failure to mount a 
delayed reaction to BCG protoplasm would indicate a failure 
of- the sensitized lymphocytes to respons to the antigen. 
The reverse experiment was also performed. Lymphocytes 
from BCG sensitized mice were injected into unimmunized 
recipients which had been pretreated with PHA. Failure to 
mount a delayed reaction in this case would indie; te that 
the primary action of PHA had been upon tlie recipient's 
macrophages. 
IN VIVO TUMOR CHALLENGE EXPERIMENTS 
Survival Time 
liice were treated with a single injection of PHA either 
24 hr before or after the injection of tumor cells. The 
concentration of PHA was varied between groups. Tumor cells 
were prepared in l-iJil.'i, and a total of 15O cells in a 0.2 ml 
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volume were injected intraperitoneally. Lice were observed 
daily, and the day of death was recorded. 
Mice were treated also with multiple injections of PHA 
at various time intervals both before and after the injection 
of 150 tumor cells, and the day of death was recorded. 
LunK Tumors 
Mice were treated with a single intraperitoneal injection 
of PliA, the concentration varied from group to group, either 
24 hr prior to, or subsequent to, the injection of 1 x 10^ 
tumor cells into the tail vein. After 21 days the mice were 
killed, and the lungs were removed and immersed in Plutzniks 
fixative (80) for 24 hr. Plutzniks solution consisted of 
91 parts of 70fo ethanol, 4.5 parts formalin, and 4.5 parts 
acetic acid. After 24 hr the lungs were removed from the 
fixative, and the number of surface, lung tumors visible with 
3OX magnification were counted. 
IN VITRO CYTOTOXICITY ASSAYS 
iviice were divided into 4 groups of I8 animals each. 
Group 1 served as controls and received no treatment. Groups 
2 and 3 were injected intraperitoneally with 250 tumor cells 
on day zero, while r:roupa 3 and 4 were injected intraperiton­
eally with 400 ug PxIA on day -1. At 5 or ? day intervals 3 
mice from each group were killed, and their cells were 
pooled and tested for in vitro cytotoxicity toward tumor 
cells. Cells and serum for all cytotoxicity tests were 
obtained L'ro ;ii  tiiese ;"rou,,s of mice. 
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liacroT)hap;e Cytotoxicity Assay 
Peritoneal exudate cells were harvested from PHA-treated 
mice and untreated mice at various time intervals after the 
intraperitoneal injection of 250 tumor cells. Mice were 
killed by cervical dislocation, immersed in a dilute 
amphylsolution, and carefully skinned without rupturing the 
peritoneal cavity. Four ml of cold DPBS were injected into 
the,peritoneal cavity with a 27ga needle. The cavity was 
massaged gently and then swabbed 70^ ethanol. Peritoneal fluid 
was withdrawn into a syringe with an l8ga needle and added 
to siliconized conical centrifuge tubes kept on ice. The 
peritoneal fluid from 3 mice was pooled, and the tubes were 
centrifuged at ^^^xg for 5 min at 4°C. The cell pellets were 
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resuspended in InEM + PCS to a concentration of 1 x 10 viable 
cells/ml, A 0.1 ml portion, containing 10^ cells, was 
spotted in the center of a 24 mm plastic coverslip (Lux tflv. 
Thousand Oaks, CA.) contained in a 35 mm petri dish (Falcon, 
Oxnard, CA.) and incubated in a humidified container for 
45 min in an atmosphere of 5/^ COg and 95'/® air. Following 
incubation, the coverslips were rinsed three times with 
streams of 2 ml cold DPBS dispensed from a Cornwall continuous 
pipetting apparatus to remove all nonadherent cells. The 
cell;j remaining after washing formed a spot of approximately 
1 cm in dlcUneter and were considered to be predominantly 
macrophages. A total of 3-0 x 10^ tumor cells in a 3 ml 
volume were added to tiie petri dishes and incubated at 37^0 
for 72 hr in a humid atmosphere of 5% CO and 95;-5 air. 
Expended medium v/as replaced with fresh i.iedium after 24 and 
48 hr of incubation. Following incubation, the coverslips 
were removed from their dishes, rinsed three times in DPBS, 
and fixed for 5 min with methanol. The coverslips were 
then stained for 60 sec with a 0.1^^ solution of crystal 
violet, rinsed, and dried. The stained coverslips were 
Mounted on microscope slides and observed by lig^it microscopy 
under h if: h power (450X). The number of tumor cells in 10 
lii.'ih power fields (hpf) were counted, and each assay was 
performed in duplicate so tliat a total of 20 high power 
fields were observed. The average number of tumor cells 
per hi^h power field was determined, and the percent 
cytotoxicity was calculated by comparing test cultures to 
normal cultures by the following formula: 
X 100 = % cytotoxicity 
K = Mean number of tumor cells/hpf in normal cultures 
T = Wean number of tumor cells/hpf in test cultures 
l-.acrophages from mice immunized with BCG have been 
shown to be cytotoxic for Bl6 tumor cells in macrophage 
cytotoxicity tests (43). Macrophages obtained from mice 
vaccinated 14 days previously with BCG were used as positive 
controls in all macropha e cytotoxicity assays. These 
macro)hage-rich cell preparations continually manifested 
between 55 - 70/) cytotoxicity in all tests. 
The effect of in vitro PHA treatment on BCG-sensitized 
mice was investigated also to determine whether PHA could 
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alter the response ox their activated macrophages in 
macrophage cytotoxicity assays. 
Lymphocyte Cytotoxicity Assays 
ïris-buf fered Ammoniuiri chloride Separation of Spleen Cells-
I'iice were killed by cervical dislocation, and the 
spleens were ascey.tioally removed to s ; erile petri dishes 
containing r/60 mesh wire screens. Tliree spleens were pooled 
and minced through the screens into 15 ml of cold UPBS. The 
cell suspensions were transferred to conical centrifuge 
tubes on ice, and the large tissue fragments were allowed to 
sediment for 10 min. Five ml of the upper single cell 
suspension were removed to a second centrifuge tube, and the 
remainder was saved for Ficoll-itypaque separation. Tubes 
were centrifuged at 4^C for 10 rain at 400Xg, and tne cell 
pellet was resuspended in 10 ml of tris-buffered ammonium 
chloride. After 10 min incubation to lyse contaminating 
erythrocytes, the cells were centrifuged, and the supernatant 
fluid was discarded. The cell pellet was washed three times 
in DPdS by centrifugation for 5 win at 400Xg. Following the 
final wash the cell pellet was resuspended in IvlEi'.i + PCS to 
yield a final concentration of 4 x 10^ viable cells per ml. 
Viability as determined by trypan blue exceeded 80/». 
Ficoll-Hypaque Separation of Lynphocytes-
Six ml of the spleen cell suspension previously 
prepared were layered over 3 fnl. of Ficoll-Hypaque and 
centrifugcd for 20 lain (400Xg, 4^0). The lymphocyte-rich 
intarfcice was removed to a second centriftube, diluted 
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v/itîi an equal volume of DPBS, centrifuged, and the cells were 
washed three times. After the final wash the cells were 
resuspended in IviKlvi + PCS to a final concentration of 4 x 10^ 
viable cells per ml. Viability as determined by the exclusion 
of trypan blue exceeded 955^» 
Performance of Assay-
1licrotest plates (Falcon, ^3034, Oxnard, CA.) were seeded 
p 
with ?, X 10 tumor cells per well in a 10 ul volume 24 hr 
prior to testing. At the time of testing, 10 ul of the 
appropriate spleen cell suspension were added to each well to 
give 4 X 10^^ cells per well or a ratio of effector cells to 
target cells of 200:1. Plates were incubated in a humid 
atmosphere of 95/^ air and 5/o COp at 37for 48 hr. Plates 
were then rinsed three times in DPiiS, and the cells were 
finxed in methanol and stained for 1 min with 0.1# crystal 
violet. The number of tumor colonies present in the wells 
were determined microscopically. Replicates of 10 wells were 
performed for each test group, and the average number of 
tumor colonies present per well was determined. The percent 
cytotoxicity was determined as follows: 
X 100 = io cytotoxicity 
N = I'lean number of tumor colonies/well cultured with normal 
lymphocytes 
T = I'lean number of tumor colonies/well cultured with test 
lymphocytes 
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Determination of Serum Blocking Factors 
Blood was collected at various time intervals from the 
brachial artery of ether-anesthetized mice. Serum v/as 
separated from the clotted blood and frozen until tested. 
Lymphocytes from mice injected intraperitoneally with 250 
tumor cells, 18 cells days previously, were prepared by the 
Ficoll-iiypaque method and used as effector cells because of 
their known cytotoxicity (see Figure 2). Microtest wells were 
seeded with 2x10' tumor cells 24 hr prior to assay. At the 
time of testing, the medium was discarded from the plates, 
and 5 ul of test serum were added to the appropriate wells. 
Plates were then incubated with the serum for 2 hr. Ten ul 
of lymphocytes (4 x 10^/ml) were added to each well, and the 
plates were incubated and processed as previously described. 
Percent cytotoxicity was calculated by the following formula; 
X 100 = fo cytotoxicity 
N = Mean number of tumor colonies/well cultured v/ith normal 
serum 
T = i.lean number of tumor colonies/well cultured with test 
serum 
Cell Counts and Characterization of Cell Types 
All tumor cell preparations were counted microscopically 
v/ith a Spencer lieinocytonieter, and appropriate dilutions were 
prepared. Suspensions of peritoneal exudate cells and 
spleen cells were counted electronically on a Model % 
Coulter Counter (Coulter Electronics, Hialeah, FA.). 
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To determine the various cell types comprising the 
spleen cell preparations, normal spleen cells were processed 
in the usual manner, and the cell pellets were resuspended 
in twice their volume of ZZfo bovinealbumin (Ortho Diagnostic, 
Raretan, NJ.). Thin smears were made on microscope slides 
and stained with Wright's stain. The slides were examined 
microscopically, and cells were categorized according to 
morphology. Cell counts were made before and after the 
removal of the adherent cell population. By these methods it 
v/as determined that spleen cells prepared in tris-buffered 
ammonium chloride were composed of approximately 60'/o 
lymphocytes and 40^ macrophages (see Table 1). These cells 
will be referred to as spleen cell preparations. Spleen cells 
prepared by centrifugation on Ficoll-Hypaque were composed 
of approximately 90/o lymphocytes and lO'ji macrophages and will 
be referred to as lymphocyte preparations. Cytotoxicity 
assays using adherent cells and assays using Ficoll-Hypaque 
prepared lymphocytes were performed to measure the cytotoxicity 
of macropliagea and lyi.iphucytes respectively. However, to 
test for the possibility of synergistic effects between 
mixed cell populations, a spleen cell preparation (ammonium 
chloride) containing both lymphocytes and macrophages was 
also tested. 
The Effects of Contaminating kacropha/^es on Lymphocyte 
Cytotoxicity Assays 
To determine the effects, if any, of contaminating 
macrophages on lymphocyte cytotoxicity tests, 20 ul of each 
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lymphocyte cell suspension were added to I.icrotest v/ells, 
allowed to adhere for 45 min, and then rinsed vigorously 
4 
three times leaving only adherent cells. Since 8 x 10 cells 
were added of which approximately lOfo were macrophages, this 
lymphocyte cytotoxicity test. Two hundred tuiiior cells were 
added per well, and the plates were incubated for 48 hr, 
stained, and processed as described. 
The Mann-Whitney U test (69) was used to determine 
Whether two independent groups had been drawn from different 
copulations. To apply the U test, scores from tv/o independent 
groups were ranked in order of increasing size. The value 
of U (the statistic used in this test) was determined by the 
number of times the scores in the first group with n^ cases 
overlapped tuc : -i-ds in tlie second group with n^ cases. 
To compute ]] the rank of 1 was assigned to the lowest score 
in the combined (n. + n ) group of scores, the rank 2 was 
^ 2 
assigned to the next lowest score, etc. The sum of the ranks 
for each group was determined. 
= Sum of the ranks assi.-ned to the group with n, cases 
Rp - 3uiA 01 the ranks assigned to the group with rip cases 
To compute U: 
would leave o x 10^ macrophages remaining per well or 
STATISTICAL ANALYSIS 
u = n^ng + "t" l) 
——2 
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Table 1 
Characterization of Cell Types 
In Normal Spleen Cell Preparations 
Ficoll-Hypaque Separation 
A. Group Cell Counts X 10 # adherent # nonadherent 
before after 
adhering adhering 
1. 8.4 7.7 8.3# 91.7# 
2. 9.6 8.6 10.4# 89.6# 
3. 8.8 7.9 10.5# 89.9# 
Average 9.7# 90.3# 
B, Group Differential 
PI.iN's Macrophages Lymphocytes 
1. 4 8 88 
2. 1 7 92 
3. 1 94 
Avera: ;,e 2.0 6.7 91.3 
II. Ammonium Chloride Separation 
A. Group Cell Counts X 10^ % adherent % nonadherent 
before after 
adhering adhering 
1. 3.1 1.9 
2. 3.2 1.8 
3. 2.9 1.7 
Average 
39.4# 
43.2# 
40.1# 
40.9# 
60. 6# 
56. 8# 
59.9# 
59.1# 
B. Group 
1. 
2. 
3. 
Pl:M • s 
0 
2 
4 
Differential 
iacrophages 
40 
33 
Lymphocytes 
60 
65 
64 
Average 2 . 0  35-0 63.0 
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Tiie above equation which yielded the smallest value for U 
was used to determine the significance of the difference 
between the test groups. The level .of significance was read 
from the appropriate table for the computed U value. 
Defferences between groups where p<0.05 were considered 
sir:nif ican i.. 
CHAPTER 3 
RESULTS 
THE EFFECT OF PJIA TREATMENT ON THE REPONSE OF 
MICE TO IN VIVO TUMOR CHALLENGE 
Lunp" Metastases 
To determine the effect of PHi treatment on the number 
of lun^- metastases developing after intravenous tumor cell 
challenge, mice were divided into 9 groups of o mice each. 
Animals in group 1, serving as controls, received no PHA 
treatment. Mice in groups 2-5 received different amounts 
of PHA injected intaperitoneally 24 hr prior to tumor cell 
c h a l l e n g e ,  w h i l e  t h o s e  i n  g r o u p s  6 - 9  r e c e i v e d  P H A  2 4  h r  
after tumor challenge. All animals received 1 x 10^ tumor 
cells intravenously at time zero. Mice were autopsied on 
day 21, and the number of surface lung tumors were counted. 
The effect of PHA treatment on the development of lung 
metastases is summarized in Table 2. These results show 
that the treatment of mice with PHA either before or after 
tumor cell challenge could increase significantly the 
development of lung tumors. PHA given after tumor cell 
challenge appeared more effective in this respect. 
Survival Time 
The effect of PiIA treatment on the survival time of 
tumor-bearing mice was also treated. Nine groups of mice, 
8 animals per group, were injected intraperitoneally at 
t i i i i e  z e r o  w i t h  1 5 - 0  t u m o r  c o l l i , : .  A n i m u l s  i n  ;  r o u , i s  2 - 5  
were injected \,i Lli various concentrzit i ,inu oi' I'hA 24 In- befoi e 
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I'iiBLii 2 
The Effect of PllA on Lung Metastases in Lice 
Challenged iv with 1 X 10-5 
Bl6 Tumor Cells 
Group Treatment 
1 .  
2. 
3.  
4 .  
5 .  
none 
400ug PHA, d-1 
ZOOug PHA, d-1 
S On(Z 1 i A I d — 1 
5u"' fiiA, d-1 
6 . 40Oug PHA, d+1 
7. 200ug PHA, d+1 
8. 50ug iilA, d+1 
. 5'-'; : fi'A, d+1 
I.iice/group Lung tumors/mouse 
(mean8+ SD) 
8 
8 
8 
8 
8 
8 
8 
4.9 ± 2.6 
9.5 ± 4.7 
10.G + 7.2 
6.6 ̂  4.5 
5 . 0  +  2 . 1  
.041 
.041 
.253 
.439 
1 0.1 + 3 . 6  .041 
11.0 + 6.9 .032 
15.0 + ^.8 .001 
7.5 + 2.6 .003 
a. Level of significance of difference between test group' and 
control gourp 1 
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tumor cell challeiu-e, while tnose in croups 6 - 9 were 
injected with PHA 24 hr after tumor challenge. The results 
of PHA treatment on survival times are summarized in Table 3 
and show tnat treatment with PHA caused a slight decrease in 
survival time of tumor-bearinj; laice. 
To de termine './hetiier multiple i.ijections of PliA would 
be more effective than a single injection in decreasing 
survival time in tumor-bearing mice, animals were treated 
with three injections of PHA. A single injection was given 
5 days and 1 day before tumor cell challenge, and 4 days after 
tumor ciiallenge. The concentration of PHA v/as varied from 
group to goup. All mice received 150 tumor cells 
intraperitoneally on day zero. The results of multiple PHA 
injections on survival times, summarized in Table 4, show 
t lat multiple injections of PHA significantly reduced survival 
time of tumor-bearing mice at the higher doses tested. 
THE EFFECTS OP PHA VITRO CYTOTOXICITY ASSAYS 
Seventy two mice wei-e divided into 4 groups of iB mice 
eacii. nice in group 1, serving as controls, received no 
treatment. Animals in groups 2 and 3 received an intra­
peritoneal injection of 250 tumor cells on day zero. Tliis 
dose of tumor cells will l^ill normal mice in 40 - 50 days. 
Lice in groups 3 and 4 received 400 ug of PHA intraperitoneally 
on day -1. Tliree mice from each group were Killed at 5 or 7 
day intervals and their cells rmd serum pooled for 
cytotoxicity. 
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TABI,E 3 
T;ie Effect of PiiA on the Survival Time of Mice 
Challenged ip with I.5 X 10 
B1.6 Tumor Cells 
Group Treatment Nice/group Survival Time (days) 
(mean + SD) 
p®-
1. none 8 51.6 + 16.7 — — — — 
2. 400ug PliA, d-1 8 42.2 + 8.0 .287 
3. 200ug PHA, d-1 8 39.2 + 6.7 .221 
k. 50ug PHA, d-1 8 43.0 + 7.2 .368 
5. PHA, d-1 8 42.7 + 11.5 .253 
6. 400ug PHA, d+1 8 45.0 + 5.3 .439 
7. 200ug PHA, d+l 8 51.9 + 9.4 
B. PHA, d+1 8 46.8 + 5.7 .399 
9. PHA, d+l 8 48.9 + 12.1 
a. Level of significance of difference between test group and 
control group 1 
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TfiBLE 4 
The Effect of Multiple PMA Treatment on the„Survival Time 
of r.iice Challenged ip with I.5 X 10 
BI6 Tumor Cells 
Group Treatment Mice/group Survival Time 
(days) 
(mean + SD) 
1. none 6 50.1 + 12.1 
2. 400ug PHA, d-•5, -1, +4 8 36.4 + 3.6 .010 
3. 200ug PHA, d-•5, -1 »+4 8 34.5 ± 3.4 .001 
4. 50ug PHA, d-•5, -1 ,+4 8 33.6 + 2.6 .001 
5. PHA, d-•5, -l,+4 8 42.7 ± 10.2 .097 
Level of significance of difference between test group and 
control group 1 
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Idacropha/':e Cytotoxicity Tests 
Peritoneal exudate cells were pooled from 3 Jnice in each 
group for macrophage cytotoxicity testing. Mice in group 5 
served as positive controls and were inmiunized with BCG 14 
dyas prior to the performance of each assay, i-iacrophage-rich 
cell preparations feom mice immunized in this manner consis­
tently showed a high degree of cytotoxicity toward tumor cells. 
The results of the macrophage cytotoxicity assay are 
summarized in Table and Figure 1. These data show that 
macrophage-rich cell preparations from tumor-bearing mice were 
cytotoxic toward tumor cells by day 28. This cytotoxicity 
was the same v/hether or not the mice had been treated with 
PKA. 
To determine whether in vivo PHA treatment could modify 
the cytotoxic action of BCG-activated macrophages on tumor 
cells, mice were injected at various time intervals with PHA 
either before or after BCG immuni.^ation. Four groups of 
mice,, containing 3 '-lice per group, were immunized with BCG 
on day -l4. L ice in ;'.roups 2, 3» and 4 were treated intra-
peritoneally with 400 ug of PM on day -15• day -9» or day -1 
respectively. Previous results (Table 2 & 3) have shovm that 
this amount of PHA when given 1 day before tumor cell 
challenge led to increased tumor development in treated mice, 
lice in group 5 were a source of normal macrophages and 
received no treatment. Peritoneal exudate cells were 
harvested and tested i or cytotoxicity on day zero. Results 
seen in Table 6 show thnt the in vivo treatment of mice with 
PHA did not affect tlie response of theIr i^CG-activated 
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TABLE 5 
In Vitro Cytotoxicity of Macrophages from Tumor-Bearing i.iice 
for Bl6 Tumor Cells 
Source of Macrophages Mean Number of Bl6 Tumor Cells/hpf 
Group Treatment 5 10 17 24 31 38 Days 
1. none l6.7 24.4 4$.8 36.2 33.9 32.8 
2. BI6 d 0 15.5 23.0 42.4 25.7* 29.9 32.0 
3. Bl6,d 0;PHA,d-l 1^.2 23-3 '^5.4 27.1^ 29.8 32.8 
4. PHA,(i-l 15.1 22.9 42.8 38.6 32.0 33.8 
5. BCG l4d before 
aach tes^ 7.1" 9.4* 18.5^ 14.6* 10.3* 12.5* 
Indie, too a si^nificiint difference (p<.05) from control 
group 1 
FIGURE 1 
In Vitro Cytotoxicity of.Macrophages from Tumor-Bearing Mice 
for Bl6 Tumor Cells 
Source of Macrophages 
Symbols: A. BOG l4 days prior to each test 
B. 250 B16 cells, d 0 
C. 250 BI6 cells, d 0; 400 ug PHA, d-1 
D. 400 ug PHA, d-1 
70 
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40 
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1 0  
0 
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TABLE 6 
The Effect of _In Vivo PIIA Treatment on the Ability 
of BCG-Activated iiacrophages 
to Kill B16 Tumor Cells 
Group Treatment of Mice Tumor Cells/hpf % 
(mean + SD) cytotoxicity 
Day-15 Day-DÏ Da y-9 Day-1 
1. —- BOG —- 11.1 jr 6,2 6^^ 
2. PilA iiCG ——— 10.6 4] 6«2 ùo^/o 
3. BCG VtUi — 9.6+3.8 70% 
4. BOG — PHA 9.4+3.0 70'/$ 
5» — ——— — —— 31.6 + 10.3"'^ O/o 
Indicates a significant difference (p^.05) from control group 1 
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macropi.a-es tovard tumor cells at tiie concentrations or timing 
of treatments tested. 
Spleen Cell and Lymphocyte Cytotoxicity Tests, 
Three spleens, obtained fro id mice at 5 or-, y day intervals 
following tiie injection of tumor cells, were pooled for 
cytotoxicity testiric . hi,'-:h yield lymphocytes suspensions 
were prepared by cencriiugation of a portion of the spleen 
cells in a Ficoll" itypaque gradient (see Table 1). Lymphocytes 
were tested in cytotoxicity assays to determine the effect of 
PM treatment on lymphocyte cytotoxicity toward tumor cells 
(Table 7 and Figure 2). These results show a significant 
difference on day 10 between the reponse of the lymphocytes 
from tumor-bearin;;; mice and the lymphocytes from tumor-
bearing mice which had been treated with PM. Lymphocytes 
from tumor-bearing: mice treated with PliA appeared to enhance 
tumor cell growth on day 10, while those from mice not 
treated with ï'hA were cytotoxic toward tumor cells. 
A portion of the spleen cells were prepared by lysis of 
contaminating, erythrocytes with ammonium chloride, by tliis 
technique both macrophages and lymphocytes could be 
recovered (see Table l). Cytotoxicity tests employing this 
spleen cell preparation were performed to determine the 
effect of an increased inacropha^re population on cytotoxicity 
results. The data In Table '6 and Figure 3 show similar 
results to xhe lymphocyte cytotoxicity assay. Spleen cell 
cytotoxicity toward tumor cells was depressed in PILA.-treated 
tumor-bearing mice on day 10 compared to tumor-bearing mice 
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TABl# 7 
In Vitro Cytotoxicity of Lymphocytes from Tumor-bearing Mice 
for Bl6 Tumor Cells 
Source of 
Lymphocytes ivlf 3c n number tumor colonies/well 
Group Treatment 9 10 17 24 31 38 Days 
1. none 31.9 21.9 29.1 38.9 30.0 14.7 
2. Bl6, d 0 20.1* 4.2$ 7.6* 17.2* 35.9 18.8 
3. Bl6, d 0 
PHA, d-1 21.6* 39.0$ 7.4* 25.4* 27.8 20,4* 
4. PHA, d-1 23.8* 32.0* 33.9 42.0 32.9 14.0 
Indicates a significant difference (p<.05) from control 
group 1 
+ Indicates a significant difference (p<'.05) between test 
groups 2 and 3 
FIGURE 2 
In Vitro Cytotoxicity of lymphocyte from Tumor-bearing Mice 
for Bl6 Tumor Cells 
Source of Lymphocytes 
Symbols: A. 250 Bl6 cells, d 0 
B. 250 B16 cells, d 0; 400 up PHA d-1 
C. 400 ug P1IÀ, d-1 
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not treated with PHA, No synergistic effects between 
macrophages and lymphocytes were indicated by tliese results. 
Macrophage Contamination of Lymphocyte Preparations 
To determine whether part of the effects observed in 
the lymphocyte cytotoxicity tests could be attributed to 
contaminating macrophages, a cytotoxicity test was performed 
using as effector cells macrophages which contaminated the 
lymphocyte cell preparations. Each Ficoll-Hypaque cell 
suspension prepared for lymphocyte cytotoxicity testing was 
tested also for the effects of contaminating macrophages. 
These results are seen in Figure 4 and show that the 
macrophages present in the Ficoll-Hypaque lymphocyte 
preparations did not contribute significantly to the results 
of the lymphocyte cytotoxicity assay. No values were 
obtained v/liich differed significantly from zero. 
Serum Blocking Factors 
Serum was collected and pooled from 3 inice in each 
group at intervals of 5 or 7 days following tumor cell 
injection and tested for the presence of serum blocking 
factors. Lymphocytes obtained from tumor-bearing mice, I8 
dyas following the intraperitoneal injection of 250 tumor 
cells, were used as effector lymphocytes. To demonstrate 
their cytotoxicity toward tumor cells, these lymphocytes 
were compared to lymphocytes obtained from normal mice for 
tlie expression of cytotoxicity in the presence of normal 
seruiii. All scrum sn:.iples were tosteu for the presence of 
blocking factors by adding a portion of the test seruia to 
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TABLE 8 
In Vitro Cytotoxicity of Spleen Cells from Tumor-bearing Mice 
i'or Bl6 Tumor Cells 
Source of 
Spleen Cells 
Group 
1. 
2. 
3. 
4. 
Treatment 
none 
Bl6,d 0 
-il6, d 0 
PllA, d-1 
PHA, d-1 
bean nuiaber tumor colonies/well 
5 10 17 24 31 38 Days 
43.0 38.4 45.0 45.2 35.5 27.1 
37.3 17.9Ï 14.9" 22.2* 40.6 34.5 
40.2 58.4* 16.5" 31.0* 53.1 43.3% 
37.1 51.0* 50.3 47.8 44.3 24.7 
Indicates a significant difference (p-^..05) from control 
grou]j 1 
+ Indicates a si.roiifleant difference (p<.05) between test 
groirps ?, and 3 
FIGURE 3 
In Vitro Cytotoxicity of Spleen Cells from Tumor-bearing Kice 
for Bl6 Tumor Cells 
SolII'ce of Spleen Cells 
Symbols : A. 2'jU bio cells, d 0 
B. 250 BI6 cells, d 0; 400ug PHA, d-1 
C. 400ug PHA, d-1 
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lymphocyte cytotoxicity tests. ïlie results of tests for 
serurt, blocking factors are summari..;ed in Table 9 and Figure 5-
SeruiL obtained from tumor-bearing; mice was capable of 
blocking the in vItro killing of tumor cells by cytotoxic 
l.y(iiphoo""tes. The presence of serum blocking factors 
initinlly ini;re:i sed as tumor grov/tli pro;;*;i-esi;ed and then 
declined. These changes were similar v.',iet:ier or not the 
tu.Tior-bear i.n, in Lee uad been first treated with FHA. 
THU UFFUCT OF PHA Oi-i Ikl.iUNii hhSPUhbES 
Antibody Production to Sheep Red blood Cells 
The effects of PhA tre.tment on the antibody response of 
mice to sheep red blood cells are su>..iiiarized in Table 10. 
Four [groups of mice, containing 5 I'lice per '̂.rou,;, were 
employed in this testing;, bice in groups 1-3 were immunized 
inti-aperitoneally with 2 X 10^ sheep red blood cells. Iviice 
in group 2 received a sin.:'1 e injection of 400 ug of PHA 
intraperitoneally 24 hr prior to antigen, while those in 
grouo 3 received tue sa. je amount of Pi Li 24 hr r f ter the 
blood cells, animals in group 4 received no treotment. Six 
days after the immunizing dose, all mice were bled, and 
individual hemagglutinin titers were determined. The prior 
tx-eat.-ion t (if :! i ce v/ith PiLi caused a signii lean b reduction in 
their antibody response to sheep red blood cells. 
Delayed Hypersensi tIvity to BOG 
bCG-imiiiUilized mice were tr'eated with various concen­
trât ions of iiiA to deteriii i ne the effec b of treatn.enL on- the 
expression of delayed h.y pers insiti v i ty. i .ice wei e immunized 
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TABLE 9 
blockade of Lyiiiphocyte-i.^ediated Cytotoxicity by Seruiu Factors 
froKi Tuhior-beari.nr i>iice 
Source ; of Source of Tumor colonies/well Tumor 
Spleen Cells Sei'um (mean + SD) Stimulatio: 
Tumor bearing Normal 17.7 + 5.1 
Normal Normal 27.0 5.7* 52.5# 
Tumor bearing D 5 Bl6 14.5 + 6.6 
Tumor bearing Bl6,PHA 22.7 + 4.6 28.2# 
Tumor bearing PHA 19.3 ± 5.0 9.0# 
Tumor bearing D 10 Bl6 23.1 2 5.5 30.5# 
Tumor bearing Bl6,PHA 25.8 + 4.2-"- 45.8# 
Tumor bearing PHA 24.8 ± 2.4- 40.1# 
Tumor bearing D 17 1316 23.4 ± 3.3' 32.2# 
Tumor bearin; B16,PHA 26.8 + 4.9- 51.4# 
Tumor bearing PliA 26.0 + 3-3^ 32.3# 
Tumor bearing D 24 Bl6 30.9 + 3.8* 74.1# 
Tumor bearing B16,PHA 32.8 + 6.2* 85.3# 
Tumor bearing PHA 26.0 + 3.3* 46.3# 
Tumor bearing D 31 Bl6 28.3 + 4.0* 59.9# 
Tumor bearing B16,PHA 26.6 4.0* 58.3# 
Tumor bearing PHA 24.0 ± 4.2* 35.6# 
Tumor be 21 r ing D 3» Bl6 20.7 + 4.8 16.9# 
Tumor bearing Bl6,PHA 22.5 + 6.6 27.1# 
Tumor bearing PHA 16.4 + 2.7 
10.0# 
7.3# 
+ Treatment of mice: Bl6 = 250 Bl6 cells, d 0 
PHA = 400u^ VhA, d-1 
•• Indicates a si^ni ficant diffei-ence (p<.05) from control %Toup 
(line 1) 
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TABLE 10 
The Effect of PHA on Mouse Antibody Production 
to Sheet) Red iilood Cells 
Group Treatment Mice/group Mean Antibody Titer 
(Geometric mean ± SD) 
1. SRBC, d 0 5 5.6 ± 0.8 
2. SRBC, d 0 
PM, d-1 5 3.8 + 0.3 . 0l6 
3. SRBC, d 0 
PliA, d-i-1 5 5.0 + 0 .075 
4. none 5 2.8 + 0.8 .008 
a. Level of significance of difference between test group and 
control /rroup 1 
v/ith BCG on day-14 followed by Footpad testing on day zero. 
Nice in groups 2-4 were treated v/ith a single intra­
peritoneal injection of 400 ug of PHA either 1, 2, or 3 days 
prior to footpad testing. Animals in group 5 were treated 
for 3 consecutive days by injection of 400 ug of PHA per 
day followed by footpad testing on the fourth day. The 
effects of PHA treatment on tlie expression of delayed 
hypersInsitivity of BCG are summarized in Table 11. Mice 
in group 5i which had received 3 consecutive daily injections 
of PHA, showed the greatest reduction in their inflammatory 
response to BCG challenge. 
To determine v/iiether PIIA treatment of BCG-sensitized 
mice could abolish the ability of tiieir sensitized 
lymphocytes to transfer BCG sensitivity to normal mice, 
lymphocyte transfer experiments were performed. Donor mice 
were immunized with BCG on day -14, and transfer of spleen 
cells v/ere performed on day zero. Recipient mice in group 2 
and donor mice in jrroup 3 were treated v/ith 400 ug of PHA 
daily for 3 consecutive days followed by lymphocyte transer 
on the fourt i day. The effect of the transfer of normal 
lymphocytes into normal recipients v;as also tested in group 5» 
Table 12 shows that tlie administration of PHA for 3 
consecutive days efft.ctively blocked the ability of BCG-
sensi tized iymj)hocytes to transfer sensitivity to normal 
mice. Treatment of recipient mice v/ith PHA did not abolish 
the transfer of BCG sensitivity y/ith sensitized lymphocytes. 
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TABLE 11 
The Effect of PHA on tlie Delayed Hypersensitivity Response of 
la ice to BCG Proto'olasm 
Group Treatment Mice/group Increase in foot­
pad thickness (mm) 
(mean + SD) 
1. BCG, d-l4 5 0.55 + .17 — — — — 
2. BCG, 
FllA, 
d-l4 
d-1 5 0.38 .13 .041 
3. BCG, 
PHA, 
d-l4 
d-2 5 0.40 .12 .123 
k. BCG, 
PH.:t , 
d-l4 
d-3 5 0.48 + .12 .242 
r _ iiCG, 
PHA, 
d-l4 
d—1,—/ %-3 5 U.12 jr . OB .002 
6. none 5 0.18 + .13 .002 
a. Level of significance of difference between te^t A-roup 
and control ^:;;roun 1. 
5? 
TABLE 12 
The Effect of Pi IA Treatment on Passive Transfer of BCG 
Imrriuni-ty v/ltli Sensitized Lytaphocyt es 
Group bice/^roup Treri tment Increase in foot­
Donor Recipient pad thickness (mm) 
(mean + SD) 
1. 10 BCG, d-l4 Normal .28 + .13 
2. 10 BCG, d — 14 Pli A ,d-l, 
-2,-3 .28 + .10 
3. 10 
PHA, d-1,-2, 
BCG, d-l4 
-3 
Normal .15 ± .11* 
4. 10 Normal Normal .16 ± .12* 
Indicates a significant difference (p<.05) between test ^^roup 
and control 6/roup 1. 
CHAPTER 4 
DISSCUSSION 
THE EFFECT OF PHA ON THE lWi :UNE RESPONSE 
The ability of PHA treatment to reduce trie survival time 
of mice follov.'in:, tumor cell challenge v/hlch was demonstrated 
in this study, was thought to result from the intraction of 
this mitogen witli certain components of the immune system. 
Based upon tlie evidence of the present study, it was 
hypothesized that the action of PHA was upon lymphocyte 
mediated cytotoxicity. Lympliocytes exposed to P}[A were 
rendered temporarily incapaole of reacting specifically 
toward tumor cells. In fact, a few days after PHA treatment, 
lymphocytes stimulated tumor growtii in vitro. 
The present studies have shown that, following tumor 
cell challenge, treatment of mice with PHA both reduced 
their survival time and increased the development of lung 
metastases. Apparently the treatment of mice with PHA 
resulted in a suppression of the immune response, thus 
allowing for more rapid tumor development. 
In Vitro Cytotoxicity Assays 
In oi'der to expia in the effects oi PHA treatment on the 
iiiimune response of mice to tumor cells, different components 
of the itoinune system were studied. Because tumor immunity 
was believed to be mediated by T-lymphocytes (2, l6, 46) and 
macro] liages (12, 31» 49, 50), cytotoxicity tests employing 
till,se tv/(i cell iiofnilu i, ions were pex- Pormed to iJîtori iine 
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whether or not any differences existed between the cells of 
tumor-bearing mice and the cells of tumor-bearinp, mice 
treated with PllA. Evidence has been presented which showed 
that sera from tumor-beuring mice blocked the destruction of 
tumor cells by immune lymphocytes (4$, 4?, 48). These 
huiaoral blockin.^ factors might have been antibody directed 
against tumor antigens. Because PHA has been shown at times 
to enhance antibody production to antigens, sera from mice 
were collected and tested for the presence of serum blocking 
factors. 
Results showed that the presence of serum blocking-
factors was not significantly different between tumor-bearing 
mice Vvhich had been treated with PM and untreated mice. 
Interestingly, the mice ti-eated only with PHA also apparently 
produced serum factors which could protect tumor cells from 
immune lymphocytes. The reasons for this were unclear 
althougli, according to the theory of Kolb and Granger (62), 
low concentrations of lymphokines could stimulate tumor cell 
growth. Low levels of circulating PHA-induced lymphokines 
might produce a similar effect. The phenomenon of immune 
enhancement will be discussed more fully in a later section. 
Tlie data also have shown that macrophages from PHA 
treated tumor-be,ring mice and those from untreated tumor-
b ear in/': mice manifester equal cytotoxicity toward tumor cells. 
No evidence was found from this study to indicate any 
differences between these macrophage populations on their 
ability to inhiliit tumor- cell grov/th. 
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In vitro studies of tiie effect of PiiA treatment on the 
expression of lymphocyte mediated cytotoxicity, revealed 
that PHA-stimulated lymphocytes from both tumor-bearing and 
tuiQor-free mice exiiibited some early cytotoxic effects 
tovyard tumor cells. However, lymphocytes from PHA-treated 
tumor bearing mice later became refractory to antigenic 
challenge and at 10 days were incapable of responding 
specifically toward tumor cells. Lymphocytes from untreated 
tumor-bearing mice manifested cytotoxicity foi* tumor cells 
through day 24, but cytotoxicity decreased rapidly thereafter. 
This cytotoxicity appeared to represent the development of 
specific tumor immunity which gradually disappeared as tumor 
growth progressed. A similar effect was reported by 
riartholomaeus et al. (10) v/ho o served that lymphocytes 
obtained from lymph nodes draining tumors became increasingly 
more stimulatory as tumor growth progressed. 
In an attempt to relate these iji vItro results to 
in vivo observations, it was thought that during this PHA-
induced refractory period v/hen a normal immune response should 
be developing, tumor cell proliferation remained unchecked and 
was one factor responsible for the early death observed in 
Ph(A-treated tumor-bearing mice. Results als-o indicated that 
PHA-stimulated lymphocytes from both tumor-bearing and 
tumor-Tree iiice, although initially cytotoxic, later 
stimulated tumor cell proliferation _in vitro. 
The results of the spleen cell sytotoxoicity assay 
showed no si,,ni.ficant differences froia tiie lymphocyte 
cytotoxicity assay, apparently the increased percentage of 
macrophages in the spleen cell preparations had no major 
effects on the cytotoxic response. However, on day 10 the 
yield lymphocyte preparations gave slifihtly hi. h values for 
both the inhibition and for the enhancement of tumor growth 
than lid the spleen cell prepai-ations. This may indicate that 
the cells Ï,mediating these repsonses were lyrapocytes arid that 
tue greatest responses were observed in the preparations with 
a hi^h percentage of lywpliocytes. 
From these studies it appeared that the effect of PHA 
was upon lymphocyte mediated cytotoxicity. First PH% delayed 
the development of specific tumor immunity, possibly Hue'to 
tlie inability of PHA-stimulated lymphocytes- to recognize or 
to react specifi cailly with tumor cell antigens. Secondly, 
PHA-stimulated ly/nphocytes temporai'ily enhanced tumor cell 
growth. 
The Effect of PhA on T-Cell Mediated Immune Responses 
Thé results of ti.e cytotoxicity assays suggested tiiat 
T-lymphocy tes were af cted by riiA ti e i tment and tnese cells 
were temporarily incapable of specifically responding to 
antigen, To confirm this hypothesis, the effect of PHA on 
otiier T-oell u.edj.j!tod functions also was investigated. 
r ice treated with P jI a prior to anti ,,enio clinllenge with 
s lie eu red bloc J cell. ;, piuduced si gnif icantly less antibody 
than did mice not treated with PHA. Since cooperation 
between i3- and T-lym^liocytes wrs shown to l ie necessary for 
tiio cducti un oi i-uit 1--siiotai rod blwod i 1 li n L U'O-1 i os (20, 21), 
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the reduction in ant:i - sheep red blood cell titers;, observed 
in this and other, studies following PHA treatment, could 
result from the inability of T-lymphocytes to respond 
effectively to the antigen. However, anitgen processing by 
macrophages or even a direct effect u^on B-lympliocytes might 
also be involved. 
The expression of delayed hypersensitivity to BOG was 
examined also. I'he treatment of BCG-sensitized mice with 
PHA reduced significantly the delayed hypersensitivity response 
to challenge v/ith BGG protoplasm. Lymphocytes obtained from 
BCG-sensitized donors which had been treated with PHA failed 
to transfer BGG sensitivity to normal unirnmunized recipients, 
v/hile lympiiocytes fro . untreated BCG-sensitized donors were 
effective in this capacity. Since only donor lymphocytes 
Vv'liich had been exposed to PiiA failed to transfer sensitivity, 
the action of PHA appeared to be upon donor lymphocytes, 
rendering them unresponsive to the antigen. The fact t;at 
macrophages were unaffooted by this treatment was shown by this 
transfer of BCG-sensitized lymphocytes into uniuimunixed 
recipients which had Ijeen previously treated with the same 
dose of PHA. In this case only the recipient's macrophages 
had been exposed to PHA while the donor's sensitized lymphocytes 
had not. Following oliallenge with BOG protoplasm, a normal 
inflan; ,atory res )onse waa observed. These results suppoi't 
the view tiiat PHA-treated lymphocytes were less effective in 
responding to antigens than were lymphocytes which had not 
boon ex nosed to Pi . 
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CCI PARI JUL OF iîLJULTS TO OTHER RELATED STUDIES 
ilariy studies have demonstrated that lymphocytes treated 
in vitro with PHA were capable of either killin<^ tumor cells 
directly or of releasing, soluble mediators v/hich destroyed 
tumor cells (13. 40, 51-5^^-). Other studies iiave shown that 
stimulât!on of the immune system with agents such as BOG 
(9, 11) or Toxo'ola sua ) resulted in nonspecific killing 
of tumor cells, ponsibly mediated thorugh the release of 
lymphokines from sensitized lymphocytes. By analogy, it 
m in; ht appear that PHA would be similarly beneficial in 
treating malignancies, however, the present studies iiave not 
supported this view. In contrast, the ijQ vivo effects of 
PHA treatiiient on tumor .^I'owth appeared distinctly different 
from the in vitro effects. 
Otiier investigators, however, have presented evidence 
wliich suggested that jji vivo PHA treatment could result in a 
significant anti-neoplastic effect (72, 90). Robinson and 
l.ekori (90) have claimed that PHA "modified" lyinphocytes 
were capable of kill in- tumor cells _in vivo. In tlieir study 
mice were treated with P}{A prior to the injection of ascites 
tumor cells, and 7 days later the tumor volume was determined. 
When ] HA wns administered 72 lir prior to tum.or cell 
challenge, decreased numbers of tumor cells were found on 
day 7 coLipared to controls not treated v.ith PHA. However, 
when PHA was given 120 hr prior to tumor cell challenge, an 
increased tumor load was present on day 7» Nevertheless, 
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"based on these reults, the tentative use of PHA in cancer 
patients was atte:npted, and some temporary improvement was 
reported (88, 89). 
For an explanation of the results of Robinson and 
Helcori (90) to be consistent with the data presented in this 
study, it must take into account both the sequence and timing 
of changes occuring in lymphocyte populations stimulated 
with PHA. The first clian^ie observed in this study, apparent 
5 days after PH4 treati.ient, was the expression of lymphocyte 
mediated cytotoxicity toward BI6 tumor cells. This finding 
was consistent with the observations of others that lymphocytes 
treated _in vitro with FM could destroy tumor cells. It is 
not surprising, therefore, that mice given PHA 72 hr prior to 
tumor cell challenge had reduced tumor volumes (90). Tlie 
second change observed in this study appeared after 10 days 
and v;as that PIIA-stimul :i ted lymphocytes failed to respond 
specifically toward tumor cell antigens and actually stimu­
lated _in vitro tumor cell proliferation. Lymphocytes from 
untreated tuiiior-bearing mipe remained cytotoxic toward tumor 
cells at this time. Therefore, the increased tumor volume 
observed by Robinson and Wekori (90) in mice treated with 
PM 120 hr prior to tumor cell challenge, indicated that the 
Lntitial cytotoxic response of the lymphocytes was largely 
gone by this time ad indicated also an inability of lympho­
cytes to develop a specific immune response. 
Il obley et al. (72) also showed a slightly increased 
survi val time in PHA-tre:ited mi ce over normal mi ce following 
tlie Injection of ascites carcinoma. Horinal luice survived on 
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the ayeiTi-'-.e ni" lens th.'ni 8 days while PHA-treated mice 
survived for 10 days. Because of this relatively short 
survival time, it is doubtful that à specific response could, 
have effectively developed to control tumor grov/th. There­
fore, the early cytotoxic effects of PHA-treated lymphocytes 
mi.frht have played a role in prolon,'in;' survival, while cell-
mediated ii.'iiuunity was not a critical factor. 
Uesprite trie initial cytotoxic response of lymphocytes 
to PHA, the direct injection of PHA into cancer patients does 
not appear warranted based upon observations of the present 
study. The use of other nonspecific stimulants of the immune 
system, such as BOG, in combating malignancies have proven 
effective in many cases (9, ll). The action of this agent 
might be to stimulate specifically reactive lymphocytes to 
produce lymphokines which act either directly upon tumor 
cells or activate macrophages to kill tumor cells. Although 
the initial effects of BGG upon lymphocytes were immuno-
loglcally specific, tiie resulting destruction of tumor cells 
was probably noiis^^eci Tic (9). In contrast, while the 
initial action of PHA might be to promote some nonspecific 
tumor cytotoxicity, it might also block temporarily the 
development of specific tuinor immunity. One difference in 
the effect of BCG and PHA on tumor development might be due 
to the bloclcafce of specific tumor immunity by systemic PliA 
treatment. 
One possible means of avoiding the blockage of specific 
tumor .immunity while still allowing for the production of 
PiL;-induced cytotoxic lymphocytes would be to treat lympho­
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cytes vitro with UlA and to reinject them into autologous 
hosts. Cheems and Hersh (19) reported that exposure of 
lymphocytes to PHÀ in vitro prior to injecting the stimulated 
cells into subcutaneous tumor nodules, resulted in a signif­
icant anti-neoplastic effect with complete or partial 
ref^ression in 2? out of 29 nodules. Frenster and Rogoway (3^) 
also were successful in inducing regression of pulmonary 
metastases in cnncer patients in intravenous injections of 
autologous lymphocytes treated jji vitro with P?[A. 
Immune Enhancement of Tumor Growth 
The results of the lymphocyte cytotoxicity tests have 
siiown that lymphocytes from PHA-treated mice at times could 
enhance tumor cell growth. Similarly lymphocytes from mice 
with far advanced tumors also appeared to be somewhat stim­
ulatory toward tumor growth. Possibly similar effects also 
occur V i.vo and may be a contributing factor to the 
shortened survival time of PHA-treated tumor-bear in;-, mice. 
Pirt of the stimulatory effects of PHA- stimulated lymphocytes 
on tujiior :-I'owth In > dee may be due to the phenomenon of 
immuen enhancement. Prehn (8l, 82) and Prehn and Lappe (63) 
have advanced the theory that weak immune responses may 
stimulate tumor cell ^..rowth. The concept that lympheoytnr: 
'û;;ht serve as a source of essential growth factors was first 
proposed by Carrel (I?) In 1922. Carrel observed tliat 
secretory products of lymphocytes increased the proliferation 
of fibroblasts j_n vitro. Kolb and Granger (62) have presented 
ev i den ce whl ch uu; gujtud that lymphoto^-iiii. may uo the 
secretory product res, ble for tu.r et cell proliferation. 
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Lov/ concentra lions ci' lyiaphotoxin stimulated target cell 
growth while high concentrations were inhibitory. Fidler (32) 
observed tliat the mixture of small numbers of sensitized 
lymphocytes with tumor cells led to increased _in vitro tumor 
cell proliferation v/hi le lar. e numbers of sinsitized 
lymphocytes inliibltod tumor cell grov/tii. Whether soluble 
mediators, such as lymphotoxin, or direct cell-to-cell 
contact was necessary for im une enhancement still remains 
unknown. 
Investigations by others have shown that stimulation of 
lymphocytes with PJIÀ caused a release of lympnokines and 
subsequent cell division. Based upon the observations of 
Fidler (32) and Kolb and Granger (62), the immune enhancement 
theory would rpedict that as the number of PHA-responding 
lymphocytes decreased or as the lympliokine production 
decreased, an initially cytotoxic immune response would 
later become an immune enhancing response. The lymphocyte 
cytotoxicity tests performed in this study support tiiis 
assumtTion. Lymphocytes from fHA-treated mice were at first 
slightly cytotoxic tov/ard tumor cell growth on day 5 but 
stimulated tumor cell growth on day 10. Anaclerio et al. (4) 
examined the effect of m vivo concanavalin A administration 
on the develo irieint i.i spleen cell cytotoxicity. Spleen cells 
manifested the groa.tesfc cytotoxicity 24 hr after the 
intravenous injection of tlie mitogen and declined thereafter. 
On the other hand, Fidler (32) found that the ̂  vitro 
incubation of lymphocytes for 4 days with concanavalin A 
resulted iri t lelr stimulatipn of tumor cull rov/t;i when tested 
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on dsy 5. Possibly a strong early response of lymphocytes 
to T-cell mitogens resulted in the development of cytotoxic 
lymphocytes, while a declining response produced enhancing 
lymphocytes. 
Lymphocytes taken from mice which carried tumors for 
more than 30 days snowed a slight enhancing effect vitro 
on tumor cell growth. A similar effect was reported by 
Bartholamaeus et al. (10). They 0 .served tnat lymphocytes 
obtained from the lyîiiph nodes draining tumors because 
Increasingly more stiiuulatroy as tumor growth progressed. 
Whether observations of the present study were related to the 
phenomenon of immune enhancement is not known. However, as 
tumor growth progressed, the ratio of effector cells to 
tumor cells is necessearily decreased. Conceivably, this 
could result, at some point, in immune stimulation. There­
fore, in those mice in which tumors grow fastest, lymphocyte 
enhancement of tumor growth would be expected to develop 
first. Because of tlie early enhancement of tumor growth in 
mice treated with PHA, tumor growth would be accelerated 
compared to untreated mice, and lymphocyte enhancement should 
be first observable in this group. In fact, during the latter 
stages of the lymphocyte cytotoxicity tests, lymphocytes from 
PHA-treeted tumor-bearing appeared to be slightly more 
stimulatory towai'd tuinor cell grov/th than were lymphocytes 
from tumor-bearing mice. 
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PROPOSED hODWL POii I'ilii ACTION OFPHA ON THiS. IkMUNE RESPONSE 
Although PiiA has been reported by some workers to 
enhance antibody production (36, 97), other investigators have 
reported a suppression of both antibody production (lO, 24, 30» 
38, 57) and tlie development of cell-mediated iiaiaune responses 
(70, 100, 102). The theories which have been offered to 
account for these suppressive effect include, 1) the trans­
formation of imnuno-coropetent cells into blast cells which 
were inc-pable of responding to antigenic challenge (99), 
2) the preferential stimulation of a suppressor T-cell 
population capable of blocking antibody production by B-cells 
(84), 3) the blockage of draining blood vessels causing re­
tention of the antigen at the site of injection (30), 
4) the activation of macrophages resulting in the destruction 
of antigens (56), or 5) a depression in phagocytic activity 
which rediced antigen processing (66). Although other 
mechanisms also might be involved, the present studies support 
tiie view that PhA-stimulated lymphocytes were temporarily 
incapable of reacting specifically with tumor cell antigens 
and were, therefore, retarded in the development of specific 
tumor immunity. 
An understanding of the sequence of changes occuring in 
PlL'i-stlmu.lcited ly u -hocytes is necessary to explain the effect 
of PKA on immune systems. The development of lymphocyte 
mediated cytotoxicity toward tumor cells was the first 
lymphocyte response observed in this study. This initial 
cytotoxicity vv;ru: temporary and was later replaced by 
lymphocyte eniianceiaent of tumor cell f'.rowtii. At this time 
lymphocytes from untreated tumor-bearing mice remained 
cytotoxic toward tumor cells. The next change to occur in 
PHA-stimulated lymphocytes from tumor-bearing mice was a 
complete recovery of iiamune competency and the expression of 
cytotoxicity equal to that expressed by lymphocytes from 
untreated tumor-bearing ,,iice. however, tuiaor development 
would be fartlier advanced in PHA-treated mice than in 
untreated mice, and the increased tumor load would shorten 
their survival time despite the recovery of their lymphocytes 
CHAPTER 5 
SUMMARY 
The effects of PM treatment in mice on the development 
of specific tumor immunity and the subsequent effect on 
tumor growth w.s investigated. Results have shown that 
treatment of mice with PHA resulted in decreased survival 
times following intiaperitoneal tumor cell challenge. It was 
further shown that treatment of mice with PHA resulted in an 
increased number of lunr, metastases following intravenous 
challenge with tumor cells. Because of these apparently 
immunosuppressive effects of PHA on the development of tumor 
immunity, various in vitro cytotoxicity assays were performed 
to discover the specific effects of PHA on the immune system. 
i ta cru 'ha,; e cytotoxicity tests revealed no differences 
between macrophages from tumor-bearing mice which had been 
treated with PHA and the macrophages from untreated tumor-
bearing', mice. 
Assays _'.or t.-ie ui ̂ scnce of aerui;i blocking, factors 
similarly revealed no significant differences between tumor-
bearing mice and tumor-bearing mice treated with PHA, 
The evidence from this study has indicated that the 
pivliic Lfile effect of PUA was upon lymphj jjt.. . . lymphocyte 
cy to tori ci ty tests indicated that lyiiphocy tes from tumor-
bearing ifiice treated \/ith PHA were delayed in the development 
of a specific immune response as compared to untreated 
tumor-beriri.ng mice. To determine whetlier other T-cell 
11:0 j i : led j'u/a i. iiiia wore also a iVeatrd , v PHa l;i-e;<tiiient, other 
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tests were perfunned. Results inâica led that treatment of 
mice with FHA significantly reduced their antibody resyonse 
to sheep red blood cells when the PHA was given prior to the 
antigen. It v/as found also that the treatment of BGG-
imiiiunized mice with PiiA not only reduced their skin reaction 
to clir-llenfe v/it.hi tiCG protoplasm, but also abolished the 
ability of their sinsitized lymphocytes to transfer immunity 
to normal mice. 
The action of , however, did not appear to be limited 
solely to the delay in the development of tumor immunity/. 
These results have indic:,ted that PM-stimulated lymphocytes, 
w Li le temporarily cytotoxic, later stimulated tumor cell 
proliferation vitro andm therefore, may also have 
accelerated tux.or growth in WIA-treated mice. Present theories 
for file immune stimulation of tumor growth include, the 
presence of low concentrations of lymphocyte secretions, such 
as lymphotoxin, capable of stimulating tumor cell growth, or 
low ratios of effector cells to tumor cells also canaille of 
causin': increased tumor cell growth. Neither theory is 
mutually exclusive, and both actually may he stating the same 
princ i.ple. 
AltliOUfrh alternative theories have been proposed to 
explain the iininunosuppressive effects oi Plia, from these 
studies it ;-jppeared tu t tlie effect of Pha was upon lymphocyte-
mediated cytotoxicity. PhA apparently had a dual effect upon 
the iiimune response of lymphocytes to tumor cells. First PHA 
delayed the develoj>ment oi specific tuiuor ii;i;i.unity, possibly 
due to the inability of stimulated lymphocytes to react 
specifically with antigens, and secondly, PHA-stimulated 
lymphocytes temporarily enhanced tumor cell growth. 
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